Yazar "Kara Gedik, G." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Intramedullary Metastasis Detected With F-18 FDG-PET/CT
    (Elsevıer Doyma Sl, 2012) Sarı, O.; Kaya, B.; Kara Gedik, G.; Özcan Kara, P.; Varoğlu, E.
    We report F-18 FDG-PET/CT images of MRI-correlated spine metastasis from non-small cell lung cancer (NSCLC). A 50-yearold woman was admitted to hospital with shortness of breath, chest pain, back pain and hemoptysis. She had a diagnosis of nonsmall cell lung cancer by lung biopsy. F-18 FDG-PET/CT study was carried out for staging. PET/CT imaging showed a gross mass in the upper lobe of the right lung, mediastinal, right cervical and supraclavicular metastatic lymph nodes, liver metastasis and multiple bone and muscle metastasis. Also, there was an increased FDG uptake in the spine in the level of 11th thoracic vertebrae (SUVmax: 6.9). This focal lesion was an intramedullary metastasis. Correlation with MRI showed that intramedullary mass Fig. 1. A 50-year-old woman with a history of shortness of breath, chest pain, back pain and hemoptysis diagnosed as lung cancer. The patient was done PET/CT for initial imaging. PET/CT showed an increased FDG uptake in the spine at the level of 11th thoracic vertebrae (SUVmax: 6.9). This focal lesion was an intramedullary metastasis. ∗ Corresponding author. E-mail address: oktaysari@gmail.com (O. Sari). showed an heterogeneous contrast enhancement. This image was suggestive of malignant lesion (Figs. 1 and 2).
  • Küçük Resim
    Öğe
    The Role of FDG-PET/CT in Ovarian Cancer Patients with High Tumor Markers or Suspicious Lesion on Contrast-Enhanced Ct in Evaluation of Recurrence and/or in Determination of Intraabdominal Metastases
    (ELSEVIER SCIENCE INC, 2012) Sarı, O.; Kaya, B.; Özcan Kara, P.; Kara Gedik, G.; Çelik, C.; Özbek, O.; Serdengeçti, M.
    Objectives: This retrospective study was designed to investigate the role of fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in determination of recurrence and/or intraabdominal metastasis in patients with ovarian cancer having increased tumor markers or suspicious lesion detected by a contrast-enhanced abdominal CT (ceCT). Materials and methods: A total of 34 female patients who were treated for histopathologically proven ovarian cancer, underwent PET/CT examination for restaging and suspected recurrence. Patients with pathology report, tumor marker levels, ceCT and PET/CT performed within one month were included in the study. Results: A total of 34 patients were included in the study. 25 of 34 patients had high tumor marker (CA 125) level. The remaining 9 patients had suspected recurrence on ceCT imaging with normal tumor marker levels. Recurrence was confirmed by re-operation and biopsy (n = 4), clinical and imaging follow-up (n = 21) in 25 patients with elevated tumor markers. Recurrent disease was not shown in 5 of 25 patients on ceCT imaging and 1 of 25 patients on PET/CT imaging with high CA125 values. Both ceCT and PET/CT revealed recurrent disease in 19 of 25 patients. PET/CT showed more lesions in 11 of 19 patients. Sensitivity, specificity and accuracy of the PET/CT were 96.1%, 100% and 97%, respectively. Conclusion: PET/CT is found as a beneficial method for detection of the recurrence, in patients with increased serum CA 125 level and negative CT findings or with normal CA 125 level and recurrence detected by CT which was performed due to clinical symptoms.
  • Küçük Resim
    Öğe
    The Value of FDG-PET/CT in the Post-Treatment Evaluation of Endometrial Carcinoma: A Comparison of PET/CT Findings with Conventional Imaging and CA 125 as a Tumour Marker
    (ELSEVIER DOYMA SL, 2012) Özcan Kara, P.; Kara, T.; Kaya, B.; Kara Gedik, G.; Sarı, O.
    Objectives: This retrospective study was designed to assess the value of positron emission tomography/computed tomography imaging (PET/CT) in the post-treatment evaluation of the patients with endometrial carcinoma and to compare PET/CT scan with conventional imaging (Cl) including computed tomography (CT), ultrasonography (US) and magnetic resonance imaging (MRI) and CA 125 with both 20 U/ml and 35 U/ml cut-off values. Materials and methods: A total of 31 patients who were treated for histopathologically proven endometrial adenocarcinoma, underwent PET/CT examination for restaging and suspected recurrence. Thirty five PET/CT studies were performed in 31 patients. Lesion status was determined on the basis of clinical follow-up including radiological imaging (follow-up CT scan) at least 6 months and response to therapy. Results: Of the 35 PET/CT studies, 13 (37%) studies were positive, whereas 22 (63%) of them were negative. On study-based analysis the overall sensitivity, specificity, accuracy for PET/CT imaging were 100%, 96% and 97%, respectively. The corresponding information for Cl were 46%, 87% and 74%, for CA 125 (cut off= 20 U/ml) measurement were 45%, 88% and 74%, and for CA 125 (cut off = 35 U/ml) measurement were 27%, 100% and 78%, respectively. On lesion-based analysis, PET/CT revealed only one false positive case. In none of 21 patients with negative 22 PET/CT studies, no subsequent clinical or radiological recurrences were observed with a follow-up of at least 6 months. Conclusion: FDG-PET/CT is found more useful modality than CI and CA 125 in the evaluation of post-treatment endometrial carcinoma patients, for suspected recurrence.